STOCKS TELEGRAPH

Tag: Trevi

  • Strong Clinical Data Boosts Trevi Therapeutics (TRVI) Stock Value

    Strong Clinical Data Boosts Trevi Therapeutics (TRVI) Stock Value

    As of the most recent market check, shares of Trevi Therapeutics, Inc. (NASDAQ: TRVI) had increased by 36.26% to $5.86. The release of encouraging trial results, which bolstered investor confidence in the company’s treatment pipeline, is responsible for the notable increase in TRVI shares.

    Positive Results from the RIVER Trial Phase 2a

    Trevi Therapeutics’ Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) study, which evaluated Haduvio’s effectiveness in treating Refractory Chronic Cough (RCC), produced encouraging topline findings.

    In addition to demonstrating quick efficacy at the lowest dose tested, Haduvio showed advantages throughout a broad spectrum of cough severity. Furthermore, the results support the drug’s ability to treat complicated neurological cough diseases and are consistent with earlier favorable outcomes shown in chronic cough associated with idiopathic pulmonary fibrosis (IPF).

    Implications for Upcoming Progress

    Results from the RIVER study showed consistency across main and secondary objectives and were highly statistically significant. Significant improvements were also seen in patients with baseline cough frequencies that ranged from moderate to severe.

    Trevi Therapeutics hopes to address the unmet needs of people with chronic coughs by advancing the development of nalbuphine ER in response to these results. The next study is anticipated to start with regulatory guidance, and the business intends to consult with the U.S. Food and Drug Administration (FDA) on next clinical steps.

    Design and Methodology of the Trial

    A randomized, double-blind, placebo-controlled, crossover research, the Phase 2a RIVER trial assessed Haduvio’s effectiveness, safety, and tolerability in treating RCC. There was a 21-day washout time in between each 21-day therapy session.

    Using an objective cough monitor, the main endpoint evaluated the mean change in 24-hour cough frequency. All individuals with reliable cough count data at baseline and day 21 of at least one treatment session who had received at least one dosage of the study medication were included in the analysis.

    These promising results bring Trevi Therapeutics (TRVI) one step closer to filling a major treatment gap and giving patients with incapacitating and chronic cough disorders fresh hope.

  • Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results

    Trevi Therapeutics (TRVI) Gains Market Traction After Positive Trial Results

    The stock price of Trevi Therapeutics, Inc. (NASDAQ: TRVI) is increasing significantly on the US stock charts due to positive outcomes from the current Phase 2b CORAL study for patients with idiopathic pulmonary fibrosis (IPF) who have a persistent cough. After a sample size re-estimation (SSRE) investigation revealed positive results, TRVI stock gained traction, rising 17.22% as of the last check, trading at $4.22.

    Positive Outcomes from the Sample Size Re-estimation (SSRE)

    The SSRE analysis was conducted after 80 patients—50% of the planned enrollment—completed six weeks of treatment. The results indicated that no changes were necessary to the original sample size for the trial, which remains on track to achieve 75% of its target enrollment.

    As a result, Trevi Therapeutics expects the trial to continue as planned, maintaining a conditional power of 80% or greater. This outcome reaffirms the robustness of the trial design and the efficacy potential of Haduvio for treating IPF-related chronic cough.

    CORAL Trial Overview

    The CORAL trial is a double-blind, randomized, placebo-controlled study designed to evaluate the effects of three doses of Haduvio (27mg, 54mg, and 108mg twice daily) on chronic cough in IPF patients.

    Trevi Therapeutics will be randomizing approximately 160 participants into one of four groups: three doses of Haduvio or a placebo, with each group undergoing a 6-week treatment period. The trial’s primary efficacy endpoint is the change in 24-hour cough frequency, measured objectively through the VitaloJAK cough monitor. Secondary endpoints will include patient-reported outcomes on cough severity.

    Reaffirming the Trial’s Design and Efficacy

    The successful SSRE outcome not only supports the trial’s continued progress with the original sample size but also strengthens the efficacy observed in Trevi Therapeutics’ earlier Phase 2a CANAL trial. This milestone underscores TRVI’s confidence in Haduvio’s potential as a first-in-class treatment for IPF chronic cough, a condition that currently lacks approved therapies.